Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are collecting detailed data over time on people with advanced non-small cell lung cancer NSCLC who have a specific genetic change called METex14 skipping alterations. This observational disease registry aims to understand how treatments and outcomes evolve for these patients, without changing their usual medical care. It is conducted across multiple countries to gather high-quality, standardized information on this particular lung cancer subgroup. Participants in this registry receive systemic therapy as determined by their doctors in routine clinical practice, without any treatments imposed by the study. Data collection starts when participants join the registry and continues through their treatment and follow-up, until death, loss to follow-up, entry into another clinical trial, or the end of the registry period. The registry does not involve administering any study drugs or interventions. Throughout the study, researchers collect information on participant demographics, clinical features including biomarker data, treatment patterns, and safety. They monitor outcomes such as tumor response using standardized criteria, overall survival, and adverse events. Data collection continues up to nearly five years to capture long-term results, providing valuable insights into real-world treatment effectiveness and patient safety over time.